Search clinical trials for: Cell cycle signaling pathway aberrations

Total 51998 results

Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Chile, Malaysia, Brazil, Guatemala, China, Taiwan, South Africa, Colombia, United States, Ukraine, Australia, Mexico, Romania
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
Dongzhimen Hospital, Beijing

Recruiting

Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited

Syndrome | Knee Osteoarthritis | Traditional Chinese Medicine

China
M.D. Anderson Cancer Center

Recruiting

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
University of Pennsylvania

Recruiting

Lentivirally Redirected CD123 Autologous T Cells in AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Refractory

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Ph-Like Acute Lymphoblastic Leukemia | Refractory Ph-Like Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Uterine Cervical Neoplasms | Small Cell Lung Carcinoma | Ovarian Neoplasms | Carcinoma, Neuroendocrine | Extrapulmonary Small Cell Cancer | Carcinoma, Non-Small -Cell Lung

United States
Diwakar Davar
Aculeus Therapeutics

Active, not recruiting

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NSCLC | Metastatic Colorectal Carcinoma | Refractory Melanoma

United States
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
National Cancer Institute (NCI)

Completed

M7824 in Subjects With HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Human Papilloma Virus | Vaginal or Penile Cancer

United States
AbbVie
Roche-Genentech

Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
Lithuanian University of Health Sciences
University of Groningen; Research Council of Lithuania

Unknown

Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma (ECMA)

Extracellular Matrix Alteration | Allergic Asthma | Airway Remodelling

Lithuania
Arbor Life Labs

Completed

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss (REBOOT-MEN)

Androgenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning Hair

United States
Arbor Life Labs

Completed

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss (REBOOT-WOMEN)

Androgenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning Hair

United States
GlaxoSmithKline

Completed

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Neoplasms

United States, Denmark, Spain, Belgium, United Kingdom, Russian Federation, Netherlands
University of Miami

Terminated

Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients

Esophageal Cancer

United States
Novartis Pharmaceuticals

Withdrawn

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Withdrawn

Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

Thymoma | Autoimmune Disease

China
Peking University Cancer Hospital & Institute
Kiang Wu Hospital

Unknown

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Melanoma
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Sarcoma | Lymphoma | Brain Neoplasms | Osteosarcoma | Wilm's Tumor

United States
University of North Carolina, Chapel Hill
Tibotec Pharmaceutical Limited

Completed

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Hepatitis C

United States
Cancer Research UK

Completed

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

United Kingdom
Centre Hospitalier Universitaire de Saint Etienne
Institut de Cancérologie de la Loire; Groupe de Recherche sur la Thrombose

Completed

Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (METRO)

Multiple Myeloma

France
Boston University
Merck Sharp & Dohme LLC

Withdrawn

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Pruritus

United States
Children's Oncology Group
National Cancer Institute (NCI); Pediatric Oncology Group

Completed

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Brain Tumors | Central Nervous System Tumors

United States, Puerto Rico, Switzerland, Australia, Canada
National Cancer Institute (NCI)

Completed

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Endometrial Papillary Serous Carcinoma

Canada
First Affiliated Hospital, Sun Yat-Sen University
Guangdong Province, Department of Science and Technology

Unknown

VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC) (VEGF ECC)

Extrahepatic Cholangiocarcinoma

China
Memorial Sloan Kettering Cancer Center

Completed

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
First Affiliated Hospital, Sun Yat-Sen University
Guangdong Province, Department of Science and Technology

Unknown

VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (icc)

Intrahepatic Cholangiocarcinoma

China
First Affiliated Hospital, Sun Yat-Sen University
Guangdong Province, Department of Science and Technology

Unknown

VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway (HCC)

Hepatocellular Carcinoma

China
Yanyan Liu

Recruiting

Linperlisib Combined With Chidamide in Patients With PTCL

Peripheral T-cell Lymphoma

China
N.N. Petrov National Medical Research Center of...

Recruiting

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors (GERMAN)

Germ Cell Tumor

Russian Federation
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis | Systemic Sclerosis - Diffuse Cutaneous | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
West China Hospital

Not yet recruiting

Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage ⅢA
Fudan University

Recruiting

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Solid Tumor

China

Search clinical trials for: Cell cycle signaling pathway aberrations

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations